Shruti Bhat PhD, MBA, Operations Excellence Expert
  • Home
  • Shruti
  • Operational Excellence Hub
  • OpEx Models
  • Writings
    • Process Improvement
    • Business Transformation
    • Innovation Management
    • Leading Research and Development
    • Developer's Diary
    • Business Continuity
    • Change Management
    • Digital Transformation
    • Quality Improvement and Compliance
    • Free eBooks and Whitepapers
    • Checklists and Templates
  • Books
  • Services
    • PharmaOps Consulting
    • Tara LeanWorks
    • Training Services
  • Blog
  • Insights
  • Case Studies
  • Patents
  • Print Publications
  • Videos
  • Contact

Poka-Yoke Enterprise OpEx Model: Designing Error-Proof Operational Excellence Systems for Pharma, MedTech and Advanced Manufacturing

3/10/2026

0 Comments

 
Spotlight: Most companies try to fix errors by adding more training, more SOPs and more inspections. Yet deviations keep recurring. Why?

Because most quality systems are built around human vigilance, not system design. Poka-Yoke flips the equation. Instead of asking people to be perfect, it designs systems where mistakes cannot easily occur.

When applied at enterprise scale, Poka-Yoke becomes far more than a manufacturing or a service tool—it becomes a complete Operational Excellence model for designing reliability into the system itself.

In this post I explore:
  • Why human-centered quality systems fail
  • How Poka-Yoke differs from CAPA
  • Why error-proofing must become an enterprise design philosophy
  • A 5-stage enterprise implementation roadmap
  • A Poka-Yoke maturity model for prevention capability
The result is a shift from detecting errors → eliminating error opportunity.

Operational excellence is not about asking people to perform perfectly. It is about designing systems where failure cannot survive.

Checkout the full post below…
poka yoke operational excellence model
Introduction: The Limits of Human-Centered Quality Systems
Most traditional quality systems assume that human operators can reliably execute procedures when properly trained and supervised. Consequently, organizations invest heavily in standard operating procedures, training programs, supervisory oversight, and inspection layers designed to ensure compliance.

However, research across multiple industries consistently shows that human error remains one of the most significant contributors to operational failures. Even well-trained people operating within robust procedural frameworks can make mistakes when confronted with complex instructions, ambiguous information, or demanding work environments. These risks increase in industries characterized by high product variability, tight production schedules, and strict regulatory oversight.

Operational excellence frameworks historically attempted to mitigate this risk by introducing additional checks and balances. Organizations add inspection steps, introduce secondary verification processes, expand approval layers, and reinforce training requirements. While these interventions can improve error detection, they rarely eliminate the root opportunity for mistakes to occur.

Poka-Yoke introduces a fundamentally different philosophy. Instead of assuming that errors will occur and must therefore be detected, Poka-Yoke seeks to remove the conditions that allow errors to happen in the first place. By embedding correctness into the design of systems, processes, and interfaces, organizations can dramatically reduce their reliance on human vigilance.
 

Understanding Poka-Yoke: Designing for Error Prevention
The concept of Poka-Yoke originated in the Japan’s auto sector, where it was introduced as a method for preventing defects during manufacturing operations. The Japanese term “Poka-Yoke” can be loosely translated as “mistake-proofing,” reflecting the intention to design processes in which incorrect actions are either impossible or immediately detectable.

At its most basic level, Poka-Yoke mechanisms serve two functions. The first is to prevent errors entirely by physically or logically constraining how a task can be performed. The second is to detect deviations immediately and prevent those errors from propagating further through the process.

While early examples of Poka-Yoke were mechanical in nature—such as components that could only be assembled in one orientation—the concept has expanded significantly. Modern Poka-Yoke applications may involve digital systems, software validations, workflow automation, and integrated process controls. Regardless of the implementation method, the fundamental principle remains the same: the system itself ensures that incorrect actions are either impossible or immediately visible.

This approach represents a significant shift in thinking. Traditional quality management focuses on monitoring outcomes, whereas Poka-Yoke emphasizes controlling the conditions that produce those outcomes.
 
​
CAPA and Poka-Yoke: Complementary but Distinct Approaches
Corrective and Preventive Action (CAPA) systems are widely used in regulated industries to identify and address deviations. When an unexpected event occurs, CAPA frameworks guide organizations through structured investigations that identify root causes and implement corrective actions to prevent recurrence.

While CAPA is an essential component of modern quality management systems, it is inherently reactive in many situations. The process begins only after a failure, deviation, or complaint has occurred. Investigations may reveal systemic weaknesses, but by the time corrective actions are implemented, resources have already been expended managing the consequences of the original problem.

Poka-Yoke addresses quality challenges from a different perspective. Rather than focusing on why a deviation occurred after the fact, Poka-Yoke encourages organizations to design systems in which the deviation cannot occur in the first place.
reactive vs preventive design
This distinction does not diminish the importance of CAPA. In fact, CAPA investigations often reveal opportunities for Poka-Yoke implementation. Root cause analysis may uncover process steps that rely excessively on operator judgment or interpretation, indicating where mistake-proofing mechanisms could provide structural protection.

In this way, CAPA and Poka-Yoke can function as complementary elements of a mature quality system. CAPA identifies systemic vulnerabilities, while Poka-Yoke eliminates them through design.
 
​

Poka-Yoke as an Operational Excellence Model
Poka-Yoke is frequently misunderstood as a collection of localized tools or devices. Organizations may implement sensors, interlocks, or checklists designed to prevent specific errors within individual processes. While these applications can deliver meaningful improvements, they remain limited in scope when applied in isolation.
​

Poka-Yoke becomes significantly more powerful when it evolves into an enterprise-wide design philosophy. In this context, mistake-proofing is no longer treated as a tactical improvement technique but as a core requirement embedded within system architecture.

​Organizations that adopt Poka-Yoke as an Operational Excellence model integrate mistake-proofing considerations into multiple layers of operational design. This includes product development, equipment engineering, process architecture, digital systems, human-machine interfaces and quality governance frameworks.
​
When applied systematically, Poka-Yoke changes the structure of operational performance. Processes become inherently more stable because the conditions that produce variability are removed during design rather than managed through monitoring and correction.
 
​
Shifting from Error Detection to Error Prevention
Traditional quality systems focus heavily on detecting errors. Inspection programs, auditing activities, and verification procedures all aim to identify defects after they occur but before they reach customers or regulators.
hierarchy of operational reliability
Although detection mechanisms are necessary, they introduce additional operational costs and complexity. Inspection steps require trained personnel, specialized equipment, and extended process timelines. Moreover, inspection processes themselves are not immune to human error.

Poka-Yoke reframes quality from a different perspective. Instead of measuring quality by the effectiveness of inspection systems, it emphasizes the elimination of error opportunities. Quality becomes a property of system design rather than a result of monitoring activities.

When organizations adopt this perspective, improvement efforts shift toward removing ambiguity from processes, simplifying decision points, and embedding correctness directly into workflows. This approach reduces the need for extensive verification activities because the system itself enforces correct behavior. 
 
​
The Importance of Interfaces in Error Prevention
Many operational improvement initiatives focus on optimizing individual tasks within a process. However, empirical evidence suggests that a large proportion of errors occur not within well-defined tasks but at the interfaces between them.
​
Interfaces include interactions between operators and machines, transitions between process stages, information handoffs between systems, and decision points where individuals must interpret complex instructions. These interfaces often introduce ambiguity, making them particularly vulnerable to error.
operational errors occur at interfaces
Poka-Yoke addresses this vulnerability by redesigning interfaces to remove ambiguity and constrain possible actions. For example, a physical connector designed to fit only one orientation eliminates the need for operators to interpret instructions about alignment. Similarly, digital systems that enforce data validation rules prevent incorrect information from entering downstream processes.

By focusing on interfaces rather than individual tasks, Poka-Yoke improves the structural integrity of the entire system.
 

Reducing Cognitive Load Through System Architecture
Traditional quality approaches frequently rely on behavioral guidance, instructing employees to follow procedures carefully and verify their work before proceeding. While these expectations are reasonable, they place significant cognitive demands on operators who must remember detailed instructions and interpret complex documentation.

Cognitive load becomes particularly problematic in environments characterized by high product variety, complex assembly sequences, or time-sensitive operations. Under these conditions, even well-trained individuals may struggle to maintain consistent performance.

Poka-Yoke mitigates this challenge by embedding decision logic directly into system architecture. Instead of requiring individuals to remember every rule, the system ensures that incorrect actions cannot easily occur. In effect, the design of the system absorbs much of the cognitive burden previously carried by operators.
​
This shift is especially important in regulated industries, where regulators increasingly emphasize robust systems capable of preventing human error rather than relying solely on procedural compliance.
 
​
Enterprise-Level Implementation
For Poka-Yoke to function as a true operational excellence model, organizations must embed mistake-proofing considerations into their governance and design processes. This requires more than isolated improvements; it requires structural integration.

Read More
0 Comments

CAPA as an Enterprise-Wide Operational Excellence Model in Life Science Companies: Transforming Quality Compliance into Strategic Continuous Improvement

3/9/2026

0 Comments

 
Spotlight: What if CAPA could do more than just close investigations and satisfy regulators?

In many life science organizations, Corrective and Preventive Action (CAPA) is triggered only after something goes wrong—a deviation, audit observation, or product complaint. But progressive pharmaceutical, biotechnology, and medical device companies must redefine CAPA as a strategic enterprise capability. By expanding CAPA beyond a quality function and embedding it across manufacturing, supply chain, regulatory, and R&D, organizations can turn it into a powerful Operational Excellence (OpEx) engine that drives continuous improvement, risk mitigation, and organizational learning.

In many life science organizations, CAPA is often treated as a compliance requirement designed to investigate deviations and resolve quality issues. However, forward-thinking pharmaceutical, biotech, and medical device companies must begin to view CAPA differently.

When implemented as an enterprise-wide Operational Excellence (OpEx) framework, CAPA becomes a strategic tool for continuous improvement, proactive risk management, and cross-functional collaboration. Instead of reacting to problems, organizations can identify systemic gaps, improve processes and strengthen quality culture across the enterprise.

As the industry evolves toward digital quality systems, predictive analytics, and integrated quality management platforms, CAPA is becoming a key driver of operational performance and regulatory readiness.

Is your CAPA process just closing investigations—or driving enterprise improvement?

Organizations that treat CAPA only as a compliance activity may be missing a major opportunity. By transforming CAPA into an enterprise-wide operational excellence framework, life science companies can improve product quality, strengthen regulatory compliance, and drive sustainable continuous improvement.
​
Now is the time to rethink CAPA—not just as a quality system requirement, but as a strategic capability for operational excellence. Checkout the full post below to know how…
CAPA as an Enterprise-Wide Operational Excellence Model in Life Science Companies: Transforming Quality Compliance into Strategic Continuous Improvement
​Life science organizations—pharmaceutical, biotechnology, medical device & prosthetics, and diagnostics companies—operate within some of the most highly regulated environments in the world. Regulatory authorities such as the U.S. FDA, EMA, and other regulatory agencies globally, require strict adherence to quality standards to ensure that the products manufactured and sold in their geographies are safe, efficacious, and comply regulations. Within this context, Corrective and Preventive Action (CAPA) has traditionally been viewed as a reactive quality management tool used to investigate deviations and prevent recurrence.

However, modern life science companies can transform CAPA from a quality subsystem into an enterprise-wide Operational Excellence (OpEx) model. In this broader framework, CAPA serves not merely as a compliance requirement but as a structured mechanism for continuous improvement, risk management, operational efficiency, and organizational learning across the enterprise.

This post explores how CAPA can function as a strategic OpEx model, its integration with enterprise processes, and the benefits it brings to life science organizations.
 
Understanding CAPA in Life Sciences
CAPA traditionally is a systematic approach used to:
  • Identify problems or nonconformances
  • Investigate root causes
  • Implement corrective actions to resolve issues
  • Establish preventive actions to avoid recurrence

Sources triggering CAPA typically include:
  • Deviations and nonconformances
  • Audit findings (internal and external)
  • Customer complaints
  • Product quality issues
  • Process failures
  • Regulatory inspections
Traditionally, CAPA has been managed within Quality Management Systems (QMS). Regulatory frameworks such as 21 CFR Part 820, ICH Q10, and ISO 13485 emphasize CAPA as a core quality process.

Yet these frameworks also encourage risk-based thinking and continuous improvement, which naturally extend CAPA beyond the quality department.
 
CAPA as an Enterprise Operational Excellence Model
Operational Excellence focuses on consistent execution, continuous improvement, and alignment of processes with strategic goals. When CAPA is implemented enterprise-wide, it becomes a structured improvement engine.

Instead of being limited to quality investigations, CAPA becomes a central governance mechanism linking multiple functions:
  • Manufacturing
  • Quality Assurance
  • Supply Chain
  • Regulatory Affairs
  • R&D
  • IT systems
  • Commercial operations
This enterprise perspective transforms CAPA into a data-driven decision-making framework.
​
Key characteristics of CAPA as an OpEx model include:
  1. Cross-functional collaboration
  2. Standardized problem-solving methodologies
  3. Data-driven root cause analysis
  4. Continuous improvement loops
  5. Enterprise-level visibility of risks and trends
 
Core Components of an Enterprise CAPA Framework
1. Integrated Quality Data Ecosystem
For CAPA to function enterprise-wide, organizations must consolidate data from multiple quality and operational systems, including:
  • Deviation management
  • Change control
  • Complaint management
  • Supplier quality systems
  • Laboratory information systems
  • Manufacturing execution systems (MES)
Integration enables trend analysis and early risk detection, shifting CAPA from reactive to proactive.
 
2. Structured Root Cause Analysis
Effective CAPA relies on disciplined problem-solving methodologies such as:

Read More
0 Comments

Ensured Label Accuracy in Pharmaceutical Packaging by Mistake-Proofing with Poka-Yoke

1/31/2025

0 Comments

 
Spotlight: Eliminate labeling errors and safeguard patient safety with innovative mistake-proofing.

In the high-stakes world of pharmaceutical packaging, precision isn’t optional—it’s essential. Faced with recurring labeling mistakes, costly recalls, and compliance challenges, one pharmaceutical company turned to Poka-Yoke, a proven mistake-proofing strategy. By integrating barcode scanning and visual verification directly into the production line, they reduced labeling errors by 95% and achieved 100% regulatory compliance. This case study demonstrates how proactive error prevention not only protects your brand but also elevates operational excellence and patient safety. Read the full case study below...
Ensured Label Accuracy in Pharmaceutical Packaging by Mistake-Proofing with Poka-Yoke
Ensured Label Accuracy in Pharmaceutical Packaging by Mistake-Proofing with Poka-Yoke- A Case Study

A North American pharmaceutical company was facing a persistent challenge with labeling errors, which led to product recalls and frequent compliance issues. Each labeling mistake posed a risk to patient safety and put the company at odds with regulatory standards, creating significant reputational and financial risks. With the high stakes of regulatory compliance in the pharmaceutical industry, the company recognized the urgency of finding an effective solution to eliminate labeling inaccuracies.

To tackle this challenge, the company implemented a Poka-Yoke system on their packaging lines. Poka-Yoke, or 'mistake-proofing' is a method designed to prevent errors at the source by integrating checks and balances directly into the process. This approach included barcode scanning and visual verification systems to ensure each label was accurate and correctly positioned. The Poka-Yoke system was set up to stop production whenever an error was detected, allowing operators to make corrections in real time before the product advanced through the packaging line. This proactive approach drastically reduced the chance for mistakes to pass through undetected.

The impact of this system was remarkable. Labeling errors decreased by more than 95%, allowing the company to maintain 100% compliance with regulatory standards. With Poka-Yoke in place, there were no further product recalls related to labeling mistakes, sparing the company from the costs and reputation damage associated with recalls. The labeling process became a seamless part of the production line, with accuracy now a built-in assurance rather than a repeated challenge.
​
This success story highlights the power of Poka-Yoke in pharmaceutical packaging.
  • Mistake-proofing pharmaceutical product development, manufacturing and logistics, Cost-savings via Poka Yoke.
By implementing mistake-proofing measures, the company not only achieved regulatory compliance but also protected its brand and ensured patient safety. Poka-Yoke proved to be an essential tool for driving operational excellence, reinforcing that error-free labeling is critical for both regulatory success and business continuity.

Ready to transform your packaging process? Let’s connect to explore how mistake-proofing can drive excellence in your operations!
Get in Touch
More Operational Excellence Case Studies at: https://www.drshrutibhat.com/blog/category/case-studies

Keywords and Tags:
#PokaYoke #PharmaPackaging #MistakeProofing #RegulatoryCompliance #LabelAccuracy #PharmaceuticalQuality #ErrorPrevention #ProductSafety #PackagingExcellence #OperationalExcellence #QualityAssurance #PharmaceuticalSuccess #ReduceRecalls #ComplianceFirst #PharmaManufacturing #PharmaceuticalPackaging #PatientSafety #Compliance #Innovation

​
Categories:  Case Studies | Life Science Industry | Operational Excellence 

​Follow Shruti on Twitter, YouTube, LinkedIn

​Subscribe to Operational Excellence Academy YouTube channel:

Picture
0 Comments

Syrup Medicines Banned in Indonesia! Isn’t there a way to formulate safe syrup products?

10/25/2022

0 Comments

 
Syrup Medicines Banned in Indonesia! Isn’t there a way to formulate safe syrup products?
The health ministry of Indonesia has temporarily banned the sale of all syrup and liquid medicines, citing the risks to children (according to a BBC news report). In a statement, the ministry explained that acute kidney injury (AKI) has been linked to syrup medicines. The government cited a sharp increase in AKI cases among children, most of them under five years of age. However, the number of acute kidney failure cases could be much higher than reported.
 
Higher than accepted levels of diethylene glycol and ethylene glycol were found to be present in the products recovered from patient’s homes. Children suffering from AKI had allegedly been using syrups that contained diethylene glycol and ethylene glycol in very small amounts. Currently, there are 206 confirmed cases of AKI in Indonesia, of which 99 were fatal. However, the true number is likely to be higher.
 
As per the BBC news report the Indonesian authorities have so far not disclosed the brands or types of syrup medicines linked to sick children; instead, just temporarily banned the sale and prescription of all syrup and liquid medicines.
 
Earlier this month, cough syrup-linked child deaths were reported from African country The Gambia. The reason then was higher than accepted levels of diethylene glycol and ethylene glycol in syrups. ( A report in India's one of the leading newspaper Economic Times stated that the Medicines Control Agency MCA, has not yet found definitive links between the deaths and the cough syrup).

Unfortunately, we have been witnessing such tragedies since 1937, when the first elixir tragedy was reported in the United States.
 
Further to that, compliance procedures and regulations were strengthened, and for a few decades, it has helped bigtime in curbing such fatalities.
 
Over the years, pharma operations have graduated from ‘quality control’ to ‘quality assurance’ and now ‘quality-by-design’. One of the fundamental principles of quality-by-design (QbD) while formulating drug products is that safety is built-into the product by design. But then a quick question that pops up in my mind is- Are syrups safe?
 
In my view and I'm sure you will agree with me, there can be no justification to such tragedies. As an operational excellence leader, I believe that in addition to ensuring cGMP and quality compliance while manufacturing drug products, it is probably the need of the hour to re-think formulation strategies for syrup medications.
 
Go for syrups sans propylene glycol!
 
This is surely a challenge for pharma formulation development scientists, but it will be efforts worthwhile. Firstly, it will stop such potential tragedies and secondly, syrups shall truly become patient-friendly!

​
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn

Categories:  Life Sciences | Mistake-Proofing

Keywords and Tags:
#Indonesiabannedsyrupmedications  #AKItragedy  #AKIchilddeaths #acutekidneyinjury  #AKI #Gambiatragedy #coughsyruplinkeddeaths #diethyleneglycol #mistakeproofingprocesses #cGMP  #GambiaChildDeaths #reformulationstrategiesforsyrups #quallitybydesign  #QbD
0 Comments

Gambia cough syrup tragedy: How can we stop such catastrophe?

10/9/2022

0 Comments

 
Gambia cough syrup tragedy- how to stop such catastrophe
Dozens of child deaths have been reported recently in African country The Gambia. The deaths are allegedly linked to cough syrups containing unacceptable levels of diethylene glycol and ethylene glycol.
 
Diethylene glycol and ethylene glycol are known toxic items and are ‘source-related’ impurities of the solvent used in the cough formulation. At the outset, for those new to this topic, let me briefly explain what is meant by ‘source- related’ impurities- There are broadly two types of impurities in drug products- (1) Source-related impurity and (2) Impurities arising as a result of product manufacturing and/or generated during the shelf-life of a product. These impurities are referred to as degradation products.
 
The source-related impurities are traces of substances in the raw material in lieu of its manufacturing. These source-related impurities cannot be totally avoided but must be controlled and must be within permissible limits mandated in the pharmacopoeia. Further, these source-related impurities must be within acceptable limits in the finished formulation (whenever that raw material is used) at all times until after the expiration of that finished formulation.
 
Same goes for the degradation products, they too (if present) must be within limits stated in the product monograph. If the impurity levels get higher than accepted limits, it can cause minor to critical safety concerns.
 
Coming back to this unfortunate incident…

​Deaths linked to diethylene glycol from cough syrup was first reported in the year 1937 in the United States, the ill-famous ‘Elixir Tragedy’.
 
Since that incident, regulators and pharma companies worldwide have put in stringent cGMP (current good manufacturing practices) criteria in drug product development thru manufacturing as well as post-marketing surveillance. The fundamental objective of cGMP is to ensure quality, efficacy and safety in drug product at all times until after its expiration. An incident such as this one, prima facie means a break-off from the norms i.e. non-compliance to the cGMP process.
 
Also, cGMP does not mean ‘best practices’ implemented only during manufacturing. cGMP is a wide-spectrum best practice and is applicable to all upstream and downstream processes of a product’s lifecycle. Non-compliance in adhering to these ‘best practices’ at any stage of the upstream and/or downstream processes can lead to mishaps, even fatalities.
 
So, what happened in this case? Why so many people died after taking a cough syrup? Why did the syrups have unacceptable quantities of diethylene glycol in them? As a member of the pharma fraternity such questions came my way (from friends and acquaintances) for the past few days. Since this matter is under investigation by competent authorities, we'll know in the coming days. But our objective as responsible pharma professionals, is not to just find out what happened in this unfortunate case, but also proactively ensure that such situations do not happen in the future.
 
In fact, I shall say- selling a safe product to the consumer is the seller’s prime responsibility, no two ways about it. Hence, not just drug products, but all products must have the desired quality attributes and must be safe in the hands of the user.  But how can companies ensure this?
 
There are several ways to achieve this. But the surest and fastest route is to- Start implementing QbD (quality-by-design) in the product’s value chain, and mistake-proof all processes in the product’s supply chain.
 
Mistake-proofing means you don’t leave any scope for errors to happen while working the process. For example, try putting a two-pin or a three-pin plug into a socket. It won’t fit-in unless inserted the right way. Another example of process mistake-proofing is a washing machine. If you were to flip open a washer’s door while it was running its cycle, the machine immediately stops. But the moment you shut back the door it re-starts! Such mistake-proofing with a plug's or washer's design and operation is to prevent accidents i.e. consumer safety.
 
Pharma companies must couple cGMP with mistake-proofing; that is, apply appropriate error-proofing measures to all its technical and business processes.
 
Some of the promising and time-tested error-proofing tools are Poka Yoke, FMEA, Visual Management, CAPA etc. I’ve separate posts on Poka Yoke and Visual Management, do check them out …

  1. Improve Process Efficiency with Visual Management
  2. Mistake-Proofing Pharmaceutical Product Development, Manufacturing and Logistics, Cost Savings via Poka Yoke
  3. Mistake-Proofing Pharmaceutical Products: What can we learn from Valsartan, Losartan and Irbesartan recalls?
  4. Valsartan, Irbesartan, Losartan Product Recalls- What are the Lessons for Pharmaceutical Industry?

News update- Subsequently, a report in India's one of the leading newspaper Economic Times stated that the Medicines Control Agency MCA and The Gambian drug regulatory authorities have not yet found definitive links between the deaths and the cough syrup, and that the cause of child deaths is still unknown.

Follow Shruti on Twitter, Facebook, YouTube, LinkedIn

Categories:  Life Sciences | Mistake-Proofing

Keywords and Tags:
#Gambiatragedy #coughsyruplinkeddeaths #diethyleneglycol #mistakeproofingprocesses #cGMP #PokaYoke  #FMEA #VisualManagement  #GambiaChildDeaths
Get In Touch
0 Comments

Out of Specification Impurity and Non-Compliance to Manufacturing Standards Continue to Haunt Pharmaceuticals- The Lupin Story.  Here's One Way to Correct the Mess ...

1/29/2019

0 Comments

 
Out of specification impurity continues to haunt pharmaceutical products. There is yet another USFDA report citing out of specification product impurity and inappropriate processing issues in a reputed pharma company!
out of specification impurity and non-compliance to manufacturing standards continue to haunt pharmaceuticals- the lupin story. Way to correct the mess
For the third time in four months, Lupin Pharmaceuticals has been admonished by the Food and Drug Administration for a series of troubling quality-control issues at a manufacturing facility.

In a recent inspection report dated January 25, 2019, the regulator cited the company for failing to thoroughly review unexplained deficiencies in batches of medicines and not taking ‘scientifically sound’ steps to evaluate samples.

Few other deficiencies include- OOS (out of specification) investigations not handled correctly, impurity levels in products exceed specification limits and detailed health hazard assessment for the presence of this impurity was not conducted as needed.

Further remarks include- failure to re-train analysts who were involved in the purported mis-identification of product impurity, CAPA (Corrective Actions Preventive Actions) not designed and implemented correctly, insufficient investigation of customer complaints.
​
Other observations include- Appropriate controls were not exercised over computers or related systems to assure that changes in master production and control records or other records are instructed only by authorized personnel; Equipment used in the manufacturing, processing, packaging or holding of drug products is not of appropriate design to facilitate operations for its intended use; Established lab control mechanisms are not documented at the time of performance, and a lack of oversight and training.

Related reading:

  1. Valsartan, Irbesartan, Losartan Product Recalls- What are the Lessons for Pharmaceutical Industry?
  2. Mistake-Proofing Pharmaceutical Products: What can we learn from Valsartan, Losartan and Irbesartan recalls?
  3. Mistake-Proofing Pharmaceutical Product Development, Manufacturing and Logistics, Cost Savings via Poka Yoke​​​.
​A detailed root cause analysis shall of course open avenues of true ‘problem areas i.e. disjointed business processes’ which need correction, followed by a neat process improvement strategy and its flawless execution.​
Ideally, pharma companies must structure a dedicated Continuous Improvement lead and team within its organogram.
​There are over eighteen different continuous improvement methodologies to choose from.
Kaizen can be an excellent start to sort out this mess.​

How to Employ Kaizen in Pharmaceutical Operations?

Though a combination of nine types of Kaizen would be most suited; for starters, Gemba Kaizen can provide maximum help.

Gemba Kaizen is a method of continuous improvement that involves real time action. It is commonly used to add valuable activities to an organization, which help to add to the quality of customer satisfaction. When a problem arises, Gemba Kaizen pinpoints the issue as promptly as possible. The solution to the problem is then used to deal with the same problem, if it should reoccur, but ideally stops the problem from reoccurring in the first place. 
​
This method also implements ideas used in lean manufacturing, which help to reduce waste and unnecessary procedures.

One of the main goals of Gemba Kaizen is to eliminate anything that is not valuable, or adds value, to an organization, whether it is systems, procedures, employees, business verticals, machinery, facility and others. 

​Kaizen Case Studies:

  1. ​​Reduced Variations in Eye Drop Dosage; a Continuous Improvement Case Study: Kaizen in Pharmaceutical Product Development
  2. Kaizen Improved Patenting and Patent Filing Process ~ 20% drop in Patenting Cost; a Continuous Improvement Case Study
  3. How to Speed-up Pharmaceutical Generic Product Development?: Continuous Improvement Case Study
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
 
​
Keywords and Tags:
​#OOS #OutOfSpecification #ProcessExcellence  #ContinuousImprovement #QualityImprovement  #ManufacturingManagement  #Pharmaceutical  #LifeSciences    #Drugs  #RiskManagement  #Lupin
0 Comments

Valsartan, Irbesartan, Losartan Product Recalls- What are the Lessons for Pharmaceutical Industry?

1/27/2019

0 Comments

 
Since September last year, news of *SARTAN drug recalls are doing the rounds. Yesterday's CNN Health carried yet another story on recalls of tainted Valsartan, Irbesartan, Losartan drug products.
Valsartan Irbesartan recalls_ What are the lessons for pharmaceutical Industry
Valsartan, Irbesartan, Losartan product recalls- What are the lessons for Pharmaceutical Industry? 

Straight answer- Big Time Business Process issue which must be rectified ASAP...

And, these 'process issues' are at several areas viz. product development process, manufacturing process, outsourcing or procurement process, customer service process to name a few; though a
company-specific root cause investigation will indicate more business processes that might have fully or partially impacted this drug product recall mess.

Presence of a potential carcinogen impurity in the drug as well as drug product clearly shows flaws in 'development and manufacturing processes'.
Companies that purchased this potentially contaminated API (active pharmaceutical ingredient) obviously have huge flaws with their 'procurement / outsourcing process' and need immediate process re-design!
​
​The fact that, carcinogen-contaminated drug products were consumed by patients show huge issues with 'customer service processes' of pharma companies and pharmacies. The issue with 'customer service process' gets further augmented because of the drug product shortage scenarios patients must now deal with.

As these recalls are not just with native irbesartan, valsartan, losartan products, but also extended to their fixed dose combinations i.e. *sartan combined with other drugs such as amlodipine, hydrochlorothiazide etc., the
product shortage mess gets sticky. Further, since these products are consumed daily, the impact of product shortages on patients (i.e. customers) is more intense...

Related reading:​

Mistake-Proofing Pharmaceutical Products: What can we learn from Valsartan, Losartan and Irbesartan recalls?
Mistake-Proofing Pharmaceutical Product Development, Manufacturing and Logistics, Cost Savings via Poka Yoke
​
Recommended steps to solve this problem:

  1. A logical thing to do in such cases is to study the Value Stream Map and identify all business processes that might have contributed to this mess.
  2. Next take a call on where these 'problematic' processes must be improved or re-designed. You can learn more about business process improvement and redesign here.
  3. Improve or redesign process(es) by using appropriate business improvement methodologies. There are over 18 different business improvement methodologies to choose from. Note that, selection of correct business process improvement methodology is very important too. 
  4. Once the problematic process(es) have been improved or redesigned as the case may be, conduct a robust risk-management exercise with FMEA and install a CAPA.
  5. ​Supplementing CAPA with Error-proofing mechanisms via Poka Yoke highly guarantees a 'no risk' scenario.​​
Follow Shruti on Twitter, Facebook, YouTube, LinkedIn
 
​
#Kaizen   #BPM #ContinuousImprovement  #QualityImprovement     #ManufacturingManagement #Pharmaceutical  #LifeSciences #Drugs #FMEA   #RiskManagement  #ErrorProofing #Losartan  #Irbesartan  #Valsartan
0 Comments
<<Previous

    New Book Released!

    Revolutionizing Industries with Lean Six Sigma

    Shruti's YouTube Channel ...

    Picture

    Blog Categories

    All
    3D Printing
    Agile
    Artificial Intelligence
    Automation
    Biotechnology
    Books
    Business Continuity
    Business Turnaround
    Case Studies
    Change Management
    Checklists
    Chemical Industry
    Continuous Improvement
    Design Thinking
    Digitalization
    Drug Delivery
    External News Links
    Hall Of Fame
    Healthcare
    Hoshin Kanri
    HR Development
    Innovation
    Insights
    ISO
    Just In Time
    Kaizen
    Leadership
    LEAN
    Lean Six Sigma
    Life Sciences
    Machine Learning
    Manufacturing
    Medical Devices & Prosthetics
    Mistake Proofing
    Motivational Cards
    MSMEs
    Nanotechnology
    Operational Excellence
    OpEx Models
    Packaging
    Patents
    Personal Products
    Process Improvement
    Product Development
    Productivity Increase
    QbD
    Quality Management
    R&D Leadership
    Robotics
    Service Industry
    Six Sigma
    Strategy
    Supply Chain Logistics
    Telecom Industry
    Templates
    TQM
    Videos
    Voice Of Customer
    Whitepaper
    Workshops

    Shruti's books...

    Picture
    top ten strategic decision-making tools for operational excellence
    shruti bhat, business process management, continuous improvement
    kaizen for pharmaceutcials, medical devices and biotech industry book by Dr Shruti Bhat
    Book on Continuous improvement tools by Dr Shruti Bhat
    kaizen for leaders, continuous process improvement tool to increase profit and organizational excellence by shruti bhat
    kaizen, shruti bhat, continuous improvement, quality, operations management
    how to lead a successful business transformation
    leading organizations through crisis
    emotional intelligence
    how to overcome challenges of creating effective teams
    modular kaizen Vs Blitz kaizen
    How to increase employee engagement as a new boss

Connect with Dr. Shruti Bhat at- ​YouTube, LinkedIn​ and X

© Copyright 1992- 2026 Dr. Shruti Bhat ALL RIGHTS RESERVED.
See Terms and Conditions details for this site usage.
Picture
Subscribe to PharmaOps Consulting YouTube Channel
Subscribe to Operational Excellence Academy YouTube Channel
​Subscribe to Operational Excellence Academy YouTube Channel
SHRUTI BHAT, CONTACT
Click to connect.
Disclaimer:
  • All content (and in all formats) provided on this site is for educational purposes only. It does not constitute legal, regulatory, quality, financial, medical or professional advice. If you wish to apply ideas contained on this site, web pages, resources bank, tools and/or blog; collectively referred to as website, you are taking full responsibility for your actions. 
  • No professional-client relationship is created by reading or using this content. 
  • ​To the fullest extent permitted by law, the author(s), Dr. Shruti Bhat and website owner disclaim liability for any loss or damage arising from reliance on the information contained herein. Read full disclaimer here before reviewing the site.
Created by Macro2Micro Media